Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022 and reiterated...

Related Keywords

Japan ,United States ,Japanese ,Neurocrine Biosciences ,Neurocrine Bioscience ,Kevin Gorman ,Neurocrine Biosciences Inc ,Sosei Group Corporation ,Linkedin ,Mitsubishi Tanabe Pharma Corporation ,Takeda Pharmaceutical Company ,Nasdaq ,Xenon Pharmaceuticals ,Japanese Ministry Of Health ,Idorsia Pharmaceuticals ,First Quarter Net Product Sales ,Product Sales Guidance Reiterated ,Chief Executive Officer ,Product Sales ,Commercial Highlights ,Japanese Ministry ,Operating Expense Guidance ,Future Milestones ,Supplemental New Drug Application ,Second Half ,Online Data ,Registrational Study ,Line Registrational Data ,Selectivet Type ,Line Phase ,Pediatric Epilepsy ,Adrenal Hyperplasia ,Major Depressive ,Onset Seizure ,Vesicular Monoamine Transporter ,Calcium Channel ,Epileptic Encephalopathy ,Continuous Spike ,Wave During Sleep ,Corticotropin Releasing Factor Type ,Isoxazole Propionic Acid ,Orphang Protein Coupled Receptor ,Sodium Channel ,Bioscience Partners ,East Asia ,Takeda Pharmaceutical Company Limited ,Webcast Today ,Quarterly Report ,Nc ,